The panel discusses emerging bladder cancer data and how the KEYNOTE-B15 results may influence perioperative treatment decisions in muscle-invasive disease. The conversation highlighted the strong outcomes seen with enfortumab vedotin plus pembrolizumab, while debating practical questions such as three versus four neoadjuvant cycles and the role of adjuvant therapy after surgery. The group also discussed how biomarkers like ctDNA could eventually help guide decisions about continuing or withholding adjuvant treatment. Overall, the discussion emphasized balancing clinical trial evidence with individualized patient care.
Contributors:
Dr. Petros Grivas is a medical oncologist and professor at the University of Washington and Fred Hutchinson Cancer Center in Seattle.
Dr. Bradley McGregor is a medical oncologist at Dana-Farber in Boston.
Dr. Ashish Kamat is a urologic oncologist at MD Anderson in Houston, Texas and president of The International Bladder Cancer Group.
Dr. Sia Daneshmand is a professor of urology and oncology at the University of Southern California, Norris Comprehensive Cancer Center.
Dr. Matthew Galsky is a medical oncologist at the Icahn School of Medicine at Mount Sinai.
Dr. Guru Sonpavde is a medical oncologist and the Phase 1 new drug development program Director at the AdventHealth Cancer Institute in Orlando, Florida.